Mostra i principali dati dell'item
Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses
dc.creator | Speletas, M. | en |
dc.creator | Argentou, N. | en |
dc.creator | Karanikas, V. | en |
dc.creator | Gramoustianou, E. S. | en |
dc.creator | Mandala, E. | en |
dc.creator | Braimi, M. | en |
dc.creator | Matsouka, P. | en |
dc.creator | Ritis, K. | en |
dc.creator | Germenis, A. E. | en |
dc.date.accessioned | 2015-11-23T10:48:10Z | |
dc.date.available | 2015-11-23T10:48:10Z | |
dc.date.issued | 2011 | |
dc.identifier | 10.1016/j.clim.2011.01.010 | |
dc.identifier.issn | 1521-6616 | |
dc.identifier.uri | http://hdl.handle.net/11615/33259 | |
dc.description.abstract | Tyrosine-kinase inhibitors are very effective in patients with CML, but in most cases the disease relapses after their discontinuation. As a result, novel approaches should be considered, such as anti-survivin treatment or anti-survivin-based immunotherapy. To gain insight into the roles of survivin isoform expression and specific CD8(+) T cells in CML, we investigated 51 patients at different stages, both at diagnosis and during treatment. We demonstrated that (i) patients at advanced-stage displayed an increased expression of the standard-survivin form along with a significant decrease of survivin-2B and -Delta Ex3 levels, (ii) patients in chronic phase with higher expression of the standard-survivin exhibited a 3.5-fold increased probability not to achieve an optimal response to imatinib (p=0.048), (iii) responders displayed a significant up-regulation of all survivin isoforms in bone marrow, and (iv) anti-survivin CD8(+) T cells were undetectable both at diagnosis and during treatment. Accordingly, our results question the validity of innmunotherapeutic approaches targeting survivin in CML. (C) 2011 Elsevier Inc. All rights reserved. | en |
dc.source.uri | <Go to ISI>://WOS:000290063100008 | |
dc.subject | Chronic myeloid leukemia | en |
dc.subject | Survivin | en |
dc.subject | Imatinib | en |
dc.subject | Cytolytic responses | en |
dc.subject | CHRONIC MYELOID-LEUKEMIA | en |
dc.subject | ANTI-APOPTOSIS GENE | en |
dc.subject | RESIDUAL DISEASE | en |
dc.subject | CELL | en |
dc.subject | DEVELOPMENT | en |
dc.subject | SPLICE VARIANTS | en |
dc.subject | CANCER-PATIENTS | en |
dc.subject | INHIBITOR | en |
dc.subject | PROTEIN | en |
dc.subject | THERAPY | en |
dc.subject | GROWTH | en |
dc.subject | Immunology | en |
dc.title | Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |